Adrenergic-drugs-Christian-James-B-Concepcion-RPh-CPS-PharmD

Chapter 9: Adrenoceptor Agonist & Sympathomimetic Drugs

Introduction

  • Effects of sympathetic stimulation mediated by release of NE from nerve terminals

  • Epinephrine acts as a hormone, NE acts as a neurotransmitter

Sympathomimetic Drugs

  • Grouped by mode of action and spectrum of receptors

  • Direct agonists: Norepinephrine and Epinephrine

  • Indirect agonists: enhance actions of endogenous catecholamines

Mechanisms of Indirect Agonists

  • Displace stored catecholamines from adrenergic nerve ending (tyramine)

  • Decrease clearance of released NE by inhibiting reuptake or preventing enzymatic metabolism

Adrenoceptor Types and Subtypes

  • Types: a, a2, B1, B2, B3, Dopamine

  • Agonists and antagonists for each subtype

Receptor Selectivity

  • Drugs may preferentially bind to one subgroup of receptors

  • Selectivity is not absolute and can interact with related classes of receptors at higher concentrations

Medical Chemistry of Sympathomimetic Drugs

  • Phenylethylamine is the parent compound

  • Substitutions can be made on the benzene ring, terminal amino group, and α & β carbons of the ethylamino chain

  • Substitution by -OH groups yields catecholamines

  • Absence of -OH groups increases bioavailability and distribution to the CNS

  • Size of alkyl substituents on the amino group increases β-receptor activity

  • Substitutions at the α carbon block oxidation by MAO and prolong drug action

  • Alpha-methyl compounds have resistance to oxidation by MAO and enhanced ability to displace catecholamines

Specific Sympathomimetic Drugs

  • Endogenous catecholamines: Epinephrine, Norepinephrine, Dopamine

  • Phenylephrine: longer duration of action, used as mydriatic and decongestant

  • Midodrine: selective α1-receptor agonist, indicated for orthostatic hypotension

  • Methoxamine: acts like phenylephrine, causes vasoconstriction and bradycardia

Direct-acting Sympathomimetics

Alpha2-selective agonists

  • Ability to decrease blood pressure through actions in the CNS

  • Direct application to a blood vessel may cause vasoconstriction

  • Examples: Clonidine, methyldopa, guanfacine, guanabenz

Dexmedetomidine

  • Sedation of initially intubated and mechanically ventilated patients in intensive care

  • Reduces requirements for opioids in pain control

Tizanidine

  • Used as a central muscle relaxant

Xylometazoline and oxymetazoline

  • Topical decongestants due to their ability to promote constriction of the nasal mucosa

Isoproterenol (Isoprenaline)

  • Very potent β-receptor agonist

  • Little effect on α receptors

Dobutamine

  • Increases cardiac output with less reflex tachycardia

  • Chemical structure resembles dopamine, but its actions are mediated mostly by activation of α and β receptors

Mixed acting Sympathomimetics

Ephedrine

  • First orally active sympathomimetic drug found in Ma huang

  • Popular herbal medication

Pseudoephedrine

  • Component of many decongestant mixtures

Phenylpropanolamine

  • Common component in OTC appetite suppressants

  • Removed from the market due to association with hemorrhagic strokes in young women

  • Can increase blood pressure in patients with impaired autonomic reflexes

Indirect-acting Sympathomimetics

Amphetamine-like

  • Enter the sympathetic nerve ending and displace stored catecholamine transmitter

  • Inhibit the reuptake of released transmitter by interfering with the action of the norepinephrine transporter (NET)

  • Examples: Amphetamine, methamphetamine, phenmetrazine, methylphenidate

Modafinil

  • Psychostimulant that differs from amphetamine

  • Used primarily to improve wakefulness in narcolepsy and other conditions

Tyramine

  • Byproduct of Tyrosine metabolism

Catecholamine Reuptake inhibitors

Atomoxetine

  • Selective inhibitor of the norepinephrine reuptake transporter

  • Used in the treatment of Attention Deficit Disorder

Reboxetine

  • Similar to atomoxetine

Sibutramine

  • Serotonin and norepinephrine reuptake inhibitor

  • Initially approved as an appetite suppressant for long-term treatment of obesity

Duloxetine

  • Widely used antidepressant with balanced serotonin and norepinephrine reuptake inhibitory effects

  • Increased cardiovascular risk has not been reported with duloxetine

  • Approved for treatment of pain in fibromyalgia

Cocaine

  • Local anesthetic with a peripheral sympathomimetic action

  • Inhibits dopamine reuptake into neurons in the CNS

Dopamine Agonist

Levodopa

  • Converted to dopamine in the body

  • Treatment of Parkinson's disease and prolactinemia

Fenoldopam

  • D1 receptor agonist that selectively leads to peripheral vasodilation in some vascular beds

  • Primary indication is in the treatment of severe hypertension

Therapeutic Uses

  • Treatment of Acute Hypotension

  • Chronic orthostatic hypotension

  • Cardiac stress test (Dobutamine injection)

  • Inducing local vasoconstriction

  • Pulmonary applications

  • Anaphylaxis

  • Ophthalmic applications

  • Genitourinary applications

  • CNS applications

  • Others: Tizanidine (muscle relaxant)

Adrenoceptor Antagonists Drugs

Introduction

  • Catecholamines play a role in many physiologic and pathophysiologic responses

  • Drugs that block their receptors have important effects

  • Effects vary according to the drug's selectivity for α and β receptors

Non-selective α antagonists

  • Used in the treatment of pheochromocytoma

  • Tumors that secrete catecholamines

α1-selective antagonists

  • Used in primary hypertension and benign prostatic hyperplasia

β-receptor antagonist drugs

  • Useful in a wide variety of clinical conditions

  • Established in the treatment of hypertension, ischemic heart disease, arrhythmias, endocrinologic and neurologic disorders, glaucoma, and other conditions

Pharmacology of the Alpha-Receptor Antagonist Drugs

  • Reversible antagonists dissociate from receptors and can be surmounted with high concentrations of agonists

  • Irreversible antagonists do not dissociate and cannot be surmounted

Specific Agents

Phenoxybenzamine

  • Binds covalently to α receptors, causing irreversible blockade

  • Inhibits reuptake of released norepinephrine

  • Used in the treatment of pheochromocytoma

  • Adverse effects: orthostatic hypotension, tachycardia, nasal stuffiness, inhibition of ejaculation

Phentolamine

  • Potent competitive antagonist at both α1 and α2 receptors

  • Used in pheochromocytoma

  • Sometimes used to reverse local anesthesia in soft tissue sites

Prazosin

  • Effective in the management of hypertension

  • Highly selective for α1 receptors

  • Relaxes both arterial and venous vascular smooth muscle

  • Extensively metabolized

  • 50% of the drug is available after oral administration

Alpha-receptor blocking drugs

Terazosin

  • Reversible α1-selective antagonist

  • Effective in hypertension

  • Approved in men with urinary symptoms due to BPH

  • High bioavailability

  • Only a small fraction of unchanged drug excreted in the urine

Doxazosin

  • Treatment of hypertension and BPH

  • Long half-life compared to prazosin and terazosin

Tamsulosin

  • Competitive α1 antagonist

  • Higher affinity for α1A and α1D receptors

  • Effective in BPH by mediating prostate smooth muscle contraction

Alfuzosin

  • α1-selective quinazoline derivative approved for use in BPH

  • Increases risk of QT prolongation in susceptible individuals

Indoramin

  • α1-selective antagonist with antihypertensive efficacy

Urapidil

  • α1 antagonist with weak α2-agonist and 5-HT1A agonist actions

  • Weak antagonist action at β1 receptors

  • Used for hypertension and BPH

Labetalol

  • Has both α1-selective and β-antagonistic effects

Chlorpromazine and Haloperidol

  • Neuroleptic drugs that are potent dopamine receptor antagonists and antagonists at α receptors

Trazodone

  • Antidepressant with the capacity to block α1 receptors

Ergotamine & Dihydroergotamine

  • Ergot derivatives that cause reversible α-receptor blockade, possibly via a partial agonist action

Yohimbine

  • α2-selective antagonist

  • Used in the treatment of orthostatic hypotension by promoting norepinephrine release through blockade of α2 receptors

Clinical Pharmacology of Alpha-receptor blocking drugs

Pheochromocytoma

  • Tumor of the adrenal medulla or sympathetic ganglion cells

  • Phenoxybenzamine is used in the management of pheochromocytoma

  • Symptoms include intermittent or sustained hypertension, headache, palpitations, and increased sweating

Hypertensive emergencies

  • Limited application of α-adrenoceptor antagonist drugs

  • Labetalol has been used in this setting

Chronic Hypertension

  • Prazosin family of α1-selective antagonists are efficacious drugs in the treatment of mild to moderate systemic hypertension

  • Prazosin is associated with dizziness

Peripheral Vascular Disease

  • Prazosin or phenoxybenzamine may benefit individuals with Raynaud's phenomenon and other conditions involving excessive reversible vasospasm in the peripheral circulation

Urinary Obstruction

  • Prazosin, Doxazosin, and Terazosin are efficacious in patients with BPH

  • Tamsulosin is also efficacious in BPH and has relatively minor effects on blood pressure at a low dose

Erectile dysfunction

  • Phentolamine combined with papaverine may cause erections in men with sexual dysfunction

Applications of Alpha2 Antagonists

  • Limited benefit in male erectile dysfunction

  • Potential use in the treatment of type 2 diabetes and psychiatric depression

Beta-Receptor Antagonist Drugs

Pharmacokinetic Properties

  • Peak concentrations occur 1-3 hours after ingestion

  • Propranolol undergoes extensive hepatic metabolism

  • Most β antagonists have half-lives in the range of 3-10 hours

  • Esmolol is rapidly hydrolyzed and has a half-life of approximately 10 minutes

  • Atenolol, Celiprolol, and Pindolol are less completely metabolized

  • Nadolol is excreted unchanged in the urine and has the longest half-life

Pharmacodynamics

  • Beta-blocking drugs lower blood pressure in patients with hypertension

  • Slowed atrioventricular conduction and increased PR interval

  • Antagonize the release of renin caused by the sympathetic nervous system

  • Fall in peripheral resistance in patients with hypertension

Effects on the Respiratory Tract

  • Blockade of β2 receptors in bronchial smooth muscle may increase airway resistance, particularly in patients with asthma

  • β1-receptor antagonists such as metoprolol and atenolol may have some advantage over nonselective β antagonists when blockade of β1 receptors in the heart is desired

Effects on the Eye

  • Reduce intraocular pressure, especially in glaucoma

Pharmacokinetic Properties of Beta-Receptor Antagonists (Page 69)

  • Chronic use of β-adrenoceptor antagonists is associated with:

    • Increased plasma concentrations of very-low-density lipoproteins (VLDL)

    • Decreased concentrations of HDL cholesterol

  • LDL cholesterol concentrations generally do not change

  • There is a variable decline in the HDL cholesterol/LDL cholesterol ratio, increasing the risk of coronary artery disease

  • β blockers with intrinsic sympathomimetic activity (partial agonists) are less likely to cause these effects

Pharmacodynamics of Beta-Receptor Antagonists (Page 70)

  • Sotalol is a nonselective Beta receptor antagonist

  • It lacks local anesthetic action

  • It has marked class III antiarrhythmic effects due to potassium channel blockade

Specific Agents (Page 71)

  • Propranolol is the prototypical β-blocking drug

  • Metoprolol and Atenolol are members of the β1-selective group

    • They are safer for patients who experience bronchoconstriction in response to propranolol

  • Nebivolol is the most highly selective β1-adrenergic receptor blocker

    • It elicits vasodilation and increases insulin sensitivity

Specific Agents (Page 72)

  • Nadolol has a very long duration of action

  • Timolol has no local anesthetic activity

    • It has excellent ocular hypotensive effects

  • Levobunolol and Betaxolol are used for topical ophthalmic application in glaucoma

  • Carteolol is a nonselective β-receptor antagonist

Specific Agents (Page 73)

  • Pindolol, Acebutolol, Carteolol, Bopindolol, Oxprenolol, Celiprolol, and Penbutolol have partial β agonist activity

    • They are effective in treating hypertension (HTN) and angina

  • Labetalol is available as a racemic mixture

    • The (S,R)-isomer is a potent α blocker

    • The (R,R)-isomer is a potent β blocker

Specific Agents (Page 74)

  • Esmolol is an ultra-short acting β-receptor antagonist

  • Butoxamine is a research drug selective for β2 receptors

Clinical Pharmacology of Beta-Receptor-Blocking Drugs (Page 75)

  • Beta-receptor-blocking drugs are used in the treatment of:

    • Hypertension

    • Ischemic Heart Disease

      • Long-term use of Timolol, Propranolol, and Metoprolol in patients with MI prolongs survival

    • Cardiac Arrhythmias

    • Heart failure

      • Metoprolol, Bisoprolol, and Carvedilol are effective in reducing mortality in selected patients with chronic heart failure

Clinical Pharmacology of Beta-Receptor-Blocking Drugs (Page 76)

  • Beta-receptor-blocking drugs are used in the treatment of glaucoma

  • Timolol is suitable for local use in the eye because it lacks local anesthetic properties

  • Betaxolol, Carteolol, Levobunolol, and Metipranolol are approved for the treatment of glaucoma

Clinical Pharmacology of Beta-Receptor-Blocking Drugs (Page 77)

  • Propranolol is used in the treatment of:

    • Hyperthyroidism, particularly in patients with thyroid storm

    • Neurologic Diseases

      • It reduces the frequency and intensity of migraine headaches

      • It reduces certain tremors (e.g., performance anxiety) and alcohol withdrawal symptoms

Southwest University Phinma Education (Page 78